Intriguing research into stock market price trends shows that investors behave strangely when a stock trades close to its 52-week high... Despite flying high, holders of the shares are more likely to sell out and snatch a profit than h...
AGL — Angle Share Price
0.000.00%
Last trade - 00:00HealthcareSpeculativeSmall CapMomentum Trap
- £243.38m
- £213.88m
- £1.01m
Momentum
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 6.03 | ||
| Price to Tang. Book | 6.62 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 240.26 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -40.89% | ||
| Return on Equity | -40.21% | ||
| Operating Margin | -1701.38% | ||
Financial Summary
| Year End 31st Dec | Unit | 2017 | 2018 | 2019 | 2020 | 2021 | 2022E | 2023E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | £m | 0.63 | 0.68 | 0.58 | 0.76 | 1.01 | 2.27 | 5.85 | 15.26% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Health Trend(F-Score)
12345678910
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Latest News & Insights for AGL
As any reader of this is probably aware, shares in Angle (LON:AGL) are currently trading close to a 52 week high, with the share price up by around 3.39% to 88.89 over the past week. On a one-month basis, the Angle price has risen by 6...
It's difficult to pick your own shares successfully – research consistently shows that more than half of retail investors in the UK and US who pick their own shares lose money. Even for skilful investors who buy a share and see it rise...
Profile Summary
ANGLE plc is a United Kingdom-based specialist medical diagnostic company, which offers products for cancer diagnostics and fetal health. The Company’s lead product is the Parsortix cell separation system, which captures very rare cells from the blood. This includes circulating tumor cells (CTCs) in cancer patient blood even when there is less than one CTC in one billion healthy cells. The Parsortix cell separation system uses a microfluidic technology in the form of a one-time use cassette to capture and then harvest circulating tumor cells (CTCs) from blood. The cassette captures CTCs based on their less deformable nature and larger size compared to other blood components. The Company’s translational research includes ovarian cancer, breast cancer, prostate cancer and small cell lung cancer.
Directors
- Last Annual
- December 31st, 2021
- Last Interim
- December 31st, 2021
- Incorporated
- December 4th, 2003
- Public Since
- March 17th, 2004
- No. of Employees
- 102
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- London Stock Exchange
- Shares in Issue
- 235,149,717
- Address
- The Surrey Research Park, 10 Nugent Road, GUILDFORD, GU2 7AF
- Web
- https://www.angleplc.com/
- Phone
- +44 1483343434
- Auditors
- RSM UK Audit LLP
Latest News for AGL
Upcoming Events for AGL
Half Year 2022 Angle PLC Earnings Release
Similar to AGL
Abingdon Health
London Stock Exchange
Advanced Medical Solutions
London Stock Exchange
Advanced Oncotherapy
London Stock Exchange
Aptamer
London Stock Exchange
Belluscura
London Stock Exchange
FAQ
What is the Angle share price?
As of Today at 19:01 UTC, shares in Angle are trading at 103.50p. This share price information is delayed by 15 minutes.
How has the Angle share price performed this year?
Shares in Angle last closed at 103.50p and the price had moved by -8.81% over the past 365 days. In terms of relative price strength the Angle share price has underperformed the FTSE All Share Index by -10.75% over the past year.
What are the analyst and broker recommendations for Angle?
The overall consensus recommendation for Angle is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Angle dividend yield?
Angle does not currently pay a dividend.
Does Angle pay a dividend?
Angle does not currently pay a dividend.
When does Angle next pay dividends?
Angle does not currently pay a dividend.
How do I buy Angle shares?
To buy shares in Angle you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Angle?
As of the previous close price of 103.50p, shares in Angle had a market capitalisation of £243.38m.
Where are Angle shares listed?
Here are the trading details for Angle:
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: AGL
What kind of share is Angle?
Based on an overall assessment of its quality, value and momentum Angle is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Angle share price forecast for 2022?
The analyst consensus target price for shares in Angle is 190.00p. That is 83.57% above the last closing price of 103.50p.
Analysts covering Angle currently have a consensus Earnings Per Share (EPS) forecast of -£0.09 for the next financial year.
What is the trend in the Angle share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Angle. Over the past six months, its share price has underperformed the FTSE All Share Index by -17.49%.
As of the last closing price of 103.50p, shares in Angle were trading -7.96% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Angle PE Ratio?
The Angle PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at 103.50p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Angle?
Angle's management team is headed by:
- Garth Selvey - NEC
- Andrew Newland - CEO
- Ian Griffiths - FID
- Jan Groen - NID
- Brian Howlett - NID